Down Syndrome and Alzheimer’s Disease.
SPECIAL REPORT: International Down Syndrome Day. Down Syndrome and Alzheimer’s Disease.
Admin
Alzheimer’s Disease Conundrum
The following article and its associated commentary were published in the February 2023 edition of MedNous.
The Alzheimer’s puzzle isn’t yet solved.
Commentary The Alzheimer’s puzzle isn’t yet solved.
US FDA approves Lecanemab for the treatment of Alzheimer’s disease.
SPECIAL REPORT #23.2 US FDA approves Lecanemab for the treatment of Alzheimer’s disease.
US Congressional report faults FDA and Biogen for Alzheimer’s drug approval
SPECIAL REPORT #22.12.5
US Congressional report faults FDA and Biogen for Alzheimer’s drug approval
You will find below the Executive Summary of the US Congressional Report on the Investigation into FDA’s Atypical Review Process and Biogen’s Aggressive Launch Plans prepared by the Staffs of the
TauRx reports confusing results with HMTM in Alzheimer’s disease treatment
TauRx reports confusing results with HMTM in Alzheimer’s disease treatment
An odd and confusing result in the 3 Lucidity trial obtained with hydromethylthionine mesylate (HMTM), a tau inhibitor, in Alzheimer’s disease patients, was reported at the Clinical Trials on Alzheimer’s disease (CTAD) conference in San Francisco, on
Alzheimer’s Disease
SPECIAL REPORT #22.6
Alzheimer’s Disease
In 2016, Baroness Professor Susan Greenfield, from Oxford University, and a group of researchers at Neuro-Bio had published an article where they showed that T14, a C terminus fragment of the acetylcholinesterase (AChE) peptide is increased in Alzheimer’s disease brains and that